Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

Rein Therapeutics priced a $50 million underwritten public offering, issuing 50 million shares at $1.00 per share. Konik Capital Partners is acting as the sole book-running manager, with the offering expected to close on May 4. The company plans to use the net proceeds to fully fund its ongoing Phase 2 clinical trial of LTI-03 in idiopathic pulmonary fibrosis. Based on its current operating plan, management believes the proceeds combined with existing cash will fund operations into 2028.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.